Ocugen Joins Forces with Kwangdong Pharmaceutical for OCU400 to Treat Retinitis Pigmentosa

Shots:Ocugen has entered into a licensing agreement with Kwangdong Pharmaceutical for OCU400 to treat retinitis pigmentosaAs per the deal, Kwangdong will receive exclusive Korean rights to OCU400 in exchange for $7.5M in upfront & near-term milestones, $1.5M per $15M in sales, reaching ≥$180M in sales milestones, plus 25% royalties on net sales, while…

ByRidhi RastogiSeptember 15, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 08, 2025 – Sep 12, 2025)  

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, and DigiHealth. Check out our full report below:   AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC Read More: AstraZeneca Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L…

ByRidhi RastogiSeptember 12, 2025

MAGAZINE

PharmaShots Magazine-September-2025 Edition

Medical psychedelics are a fascinating field that modern science has yet to comprehend completely. Researchers are still digging up, trying to find evidence-based outcomes to tap into a whole new opportunity in psychiatry and mental health medicinesThe September Edition unearths a brand-new perspective on psychedelics through engaging articles, illustrative infographics, trailing BioTrends, illuminating regulatory…

ByAditya SinghSeptember 11, 2025

NEWS

Remedium Bio Joins Forces with Eli Lilly to Advance Gene Therapies for Obesity and Type 2 Diabetes

Shots:Remedium Bio has entered into a multi-target research & development collaboration with Eli Lilly to develop gene therapies targeting multiple targets for the treatment of Obesity & Type 2 Diabetes, leveraging Remedium’s Prometheus platformAs per the deal, Remedium will receive an upfront, equity investment as well as development & commercial milestone payments, with tiered…

ByRidhi RastogiSeptember 9, 2025

NEWS

Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

Shots:Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS)As per the deal, Kaerus will receive a total of ~$450M incl. an upfront payment as well as development & commercial milestonesKER-0193 is a BK channel modulator, which showed improvement across syndrome-relevant…

ByRidhi RastogiSeptember 8, 2025

NEWS

Hengrui Pharma Enters a ~$1.08B Deal with Braveheart Bio for HRS-1893

Shots:Hengrui Pharma & Braveheart Bio have entered into an exclusive license agreement for Hengrui’s HRS-1893 to treat cardiovascular diseasesAs per the deal, Braveheart will obtain exclusive global rights (ex-China, Hong Kong, Macao & Taiwan) to develop, manufacture & commercialize HRS-1893 in exchange for $65M upfront (50% in cash + 50% in shares), ~$10M…

ByRidhi RastogiSeptember 8, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 01, 2025 – Sep 05, 2025)  

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, COVID-19, Animal Health and Biosimilars. Check out our full report below:   Merck Reports P-III (VICTOR) Trial Data of Verquvo (Vericiguat) for Chronic Heart Failure and Reduced Ejection Fraction (HFrEF) Read More: Merck AstraZeneca Reports P-III (BaxHTN) Trial Data on Baxdrostat…

ByRidhi RastogiSeptember 5, 2025

NEWS

Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions

Shots:Biocytogen has entered into an evaluation & option agreement with Merck KGaA to develop antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, incl. antibody-conjugated lipid nanoparticlesAs per the deal, Biocytogen will provide fully human antibodies from its RenMice platform for evaluation to Merck KGaA’s antibody-conjugated LNP services, with Merck KGaA holding an exclusive…

ByRidhi RastogiSeptember 4, 2025

NEWS

Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Shots:Zenas BioPharma has entered into an agreement with Royalty Pharma granting it royalty rights on the future sales of obexelimabAs per the deal, Zenas will receive ~$300M, consisting of a $75M upfront & 3 additional $75M each in milestones tied to P-III (INDIGO) trial achievement & FDA approvals in IgG4-RD & SLE, while Royalty Pharma…

ByRidhi RastogiSeptember 4, 2025

NEWS

Argo Biopharma Inks a ~$5.3B Deal with Novartis for Multiple Cardiovascular Assets, Expanding their Existing Partnership

Shots:Argo has entered into an additional strategic collaboration with Novartis for multiple CV assetsNovartis has obtained an option to license ex-China rights to two discovery-stage molecules for sHTG & mixed dyslipidemia, plus first negotiation rights to BW-00112 (ANGPTL3), a P-II asset. Deal also incl. a reciprocal P&L-sharing license for a hepatic siRNA asset…

ByRidhi RastogiSeptember 4, 2025

Ocugen Joins Forces with Kwangdong Pharmaceutical for OCU400 to Treat Retinitis Pigmentosa

PharmaShots Weekly Snapshots (Sep 08, 2025 – Sep 12, 2025)

PharmaShots Magazine-September-2025 Edition

Remedium Bio Joins Forces with Eli Lilly to Advance Gene Therapies for Obesity and Type 2 Diabetes

Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

Hengrui Pharma Enters a ~$1.08B Deal with Braveheart Bio for HRS-1893

PharmaShots Weekly Snapshots (Sep 01, 2025 – Sep 05, 2025)

Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions

Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Argo Biopharma Inks a ~$5.3B Deal with Novartis for Multiple Cardiovascular Assets, Expanding their Existing Partnership

Contact US

OUR INFORMATION

FOLLOW US